CT · Medical Imaging · Diagnostic Imaging · Artificial Intelligence
Global Institutions Collaborate to Evaluate GE HealthCare's Photonova Spectra CT System
November 16, 2026 · News Release
Source: gehealthcare.com

Seven respected healthcare institutions across North America, Europe, and Asia are set to evaluate GE HealthCare’s Photonova Spectra, a next-generation photon-counting CT system. This initiative follows the recent CE Mark, U.S. FDA 510(k) clearance, and Japan’s Pharmaceuticals and Medical Devices Agency approval, which signal the technology’s readiness for clinical adoption.
Photonova Spectra utilizes GE HealthCare’s proprietary Deep Silicon detector technology, delivering ultra-high definition imaging and spectral capabilities through a streamlined workflow. This system is designed to enhance quantitative imaging, tissue characterization, and provide new opportunities for research in spectral biomarkers.
Chad Rowland, Executive Director of Global CT at GE HealthCare, emphasized the system’s potential to improve early detection and diagnostic accuracy, stating that collaboration with the research community is essential for generating the clinical evidence necessary to enhance photon-counting CT adoption.
Evaluating Photonova Spectra Across Diverse Clinical Applications
The collaborative network of healthcare institutions will systematically assess Photonova Spectra’s image quality, spectral performance, workflow efficiency, and diagnostic utility. This research aims to broaden the understanding of photon-counting CT and generate clinical insights informing the future development of the technology.
- Keio University Hospital (Tokyo, Japan): Experts will investigate quantitative imaging techniques to evaluate Photonova Spectra’s clinical applications.
- Centro Cardiologico Monzino IRCCS (Milan, Italy): Focused on cardiovascular imaging, this institution will explore the technology’s potential for tissue characterization and workflow efficiency.
Professor Gianluca Pontone from Centro Cardiologico Monzino IRCCS remarked on the need for advanced imaging technologies in cardiovascular care, looking forward to the insights Photonova Spectra may provide.
- Universitätsspital Zürich (Zürich, Switzerland): Researchers here will focus on optimizing radiation dosage in coronary CT angiography with Photonova Spectra while maintaining diagnostic quality.
Professor Philipp Kaufmann noted the exciting prospects of combining high spatial resolution with spectral data for improving coronary imaging protocols.
- University of Wisconsin–Madison: The institution plans to further explore imaging protocols and the technology's quantitative performance, building on previous research with photon-counting CT.
- Stanford Medicine (Palo Alto, California): Researchers from Stanford will expand their studies on reconstruction methods and clinical applications of the technology, including ultra-high-resolution imaging.
Adam Wang, Assistant Professor at Stanford, highlighted the potential implications of their research for improving clinical practice and fostering scientific discovery.
Further collaborations include UZ Brussel in Belgium, assessing advanced cardiac imaging, and Rigshospitalet in Denmark, exploring pediatric and low-dose imaging applications.
Through these initiatives, GE HealthCare aims to gather clinical evidence and improve Photonova Spectra, ultimately advancing the field of photon-counting CT. For additional details, visit gehealthcare.com.
[i] Photonova Spectra is CE marked and 510(k) cleared with the U.S. FDA. Not available for sale in all regions.




